secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunovant, Inc. (IMVT)
CIK:        0001764013
Form:       8-K
Filed at:   2025-05-29T23:59:59+00:00
Accession:  0001764013-25-000091
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunovant Q4 FY2025 net loss $106.4M, cash $714M; new CEO Eric Venker
----------------------------------------------------------------------

- Net loss of $106.4M ($0.64/share) for Q4 FY2025, vs $75.3M ($0.52/share) a year ago.
- Cash and equivalents $714M as of March 31, 2025; runway through GD readout expected in 2027.
- Eric Venker, M.D. appointed CEO and Tiago Girao CFO in April 2025 as part of strategic transition.
- R&D expenses $93.7M in Q4, up from $66.1M, driven by IMVT-1402 clinical trial costs.
- Potentially registrational trials for IMVT-1402 in Sjögren's disease and second GD trial planned summer 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764013/000176401325000091/0001764013-25-000091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764013/000176401325000091/imvt-20250529.htm
  HTML page:      https://secwatch.observer/filing/0001764013-25-000091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer